TerminatedPhase 2NCT00953771
Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)
Studying Congenital thrombotic thrombocytopenic purpura
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Principal Investigator
- Ilan Shapira, M.D.Mount Sinai St. Luke's-Roosevelt
- Intervention
- Danazol(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2015
Study locations (1)
- Mount Sinai St. Luke's-Roosevelt, New York, New York, United States
Collaborators
Beth Israel Medical Center
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00953771 on ClinicalTrials.govOther trials for Congenital thrombotic thrombocytopenic purpura
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07513948Daratumumab in Immune-mediated Thrombotic Thrombocytopenic PurpuraFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- RECRUITINGNCT06441578A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraTakeda
- RECRUITINGNCT01257269Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)Insel Gruppe AG, University Hospital Bern
See all trials for Congenital thrombotic thrombocytopenic purpura →